Clinical trials: Patients With Major Depressive Disorder
Depressive Disorder, Major
Long-term, Open-label, Flexible-dose, Extension Study of Vortioxetine in Child and Adolescent Participants With Major Depressive Disorder (MDD) From 7 to 18 Years of Age
Evaluation of the long-term safety and tolerability of vortioxetine in child and adolescent participants with a Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5™) diagnosis of MDD.
- Trial name
- NCT02871297
- Testing
- Vortioxetine
- Where
- 78 sites in United States, Bulgaria and 18 more
- Volunteers
- 662 people
- Sponsor
- H. Lundbeck A/S
Depressive Disorder, Depression, Unipolar
Safety, Tolerability and Antidepressant Effects of DMT in Patients With Depression
This study aims to evaluate the acute and subacute effects of an inhaled N, N-Dimethyltryptamine (DMT) in patients with partial response in depression.
- Trial name
- NCT06094907
- Testing
- N,N-Dimethyltryptamine
- Where
- Brazil
- Volunteers
- 14 people
- Sponsor
- Universidade Federal do Rio Grande do Norte
Major Depression, Temporal Lobe Epilepsy
Escitalopram Treatment of Major Depression in Patients With Temporal Lobe Epilepsy
This is a research study evaluating the use of escitalopram (Lexapro®) for the treatment of major depression in subjects with temporal lobe epilepsy.
- Trial name
- NCT00595699
- Testing
- escitalopram
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Conrad, Erich J., M.D.
Schizophrenia, Schizoaffective Disorder
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
This study will evaluate the effectiveness of valbenazine on patient- and clinician-reported outcomes assessing health-related quality of life, functioning, and treatment effect in participants with tardive dyskinesia (TD) who…
- Conditions
- Schizophrenia, Schizoaffective Disorder, Bipolar Disorder, Major Depressive Disorder
- Trial name
- NCT05859698
- Testing
- Valbenazine
- Where
- 18 sites in United States
- Volunteers
- 59 people
- Sponsor
- Neurocrine Biosciences
Major Depressive Disorder (MDD)
Salivary Oxytocin as a Biomarker of Psychedelic Treatment
This study aims to investigate whether oxytocin reactivity during a psychedelic session for MDD treatment predicts treatment response, specifically by examining its relationship with changes in flexibility and depressive symptoms.
- Trial name
- PAPOXT_MDD (NCT07345858)
- Where
- Switzerland
- Volunteers
- 80 people
- Sponsor
- University of Geneva, Switzerland
Major Depressive Disorder
Safety and Efficacy of Vilazodone in Major Depressive Disorder
The purpose of this study was to evaluate the efficacy, safety, and tolerability of 2 fixed dose levels of vilazodone compared to placebo in patients with major depressive disorder.
- Trial name
- VLZ-MD-01 (NCT01473381)
- Testing
- Vilazodone, Citalopram
- Where
- 54 sites in United States
- Volunteers
- 1,162 people
- Sponsor
- Forest Laboratories
Major Depressive Disorder
Multimodal Imaging of ECT Effects
The project aims to investigate markers of neural activity and connectivity, neurochemistry, hypothalamic-pituitary-adrenal (HPA) axis activity, inflammation and neuronal plasticity underlying treatment response and remission…
- Trial name
- NCT02871141
- Testing
- electroconvulsive therapy, Antidepressant
- Where
- Germany
- Volunteers
- 68 people
- Sponsor
- Charite University, Berlin, Germany
Major Depressive Disorder
Efficacy of Electronic Cognitive Behavioral Therapy Application to Treat Major Depressive Disorder
The primary objective of this study is to evaluate the safety and efficacy of an electronic cognitive behavioral therapy application (eCBT Mood) compared to a control group consisting of a mood monitoring handheld computer…
- Trial name
- NCT01752608
- Testing
- eCBT Mood
- Where
- 2 sites in United States
- Sponsor
- MindApps
Depression
Pharmacogenetic Testing in an Outpatient Population of Patients With Depression
This is a randomized, control group design of pharmacogenetic implementation in a mental health population of subjects taking anti-depressants and/or anti-psychotics with a new or current primary or secondary diagnosis of Major…
- Trial name
- PGx-UPA (NCT02497027)
- Testing
- pharmacogenetic testing
- Where
- United States
- Volunteers
- 83 people
- Sponsor
- Avera McKennan Hospital & University Health Center
Major Depressive Disorder
Safety and Efficacy of Levomilnacipran ER (F2695 SR) in Major Depressive Disorder
The purpose of this study is to evaluate the efficacy, safety, and tolerability of Levomilnacipran ER versus placebo in the treatment of outpatients with major depressive disorder
- Trial name
- NCT01034462
- Testing
- Levomilnacipran ER
- Where
- 23 sites in United States
- Volunteers
- 442 people
- Sponsor
- Forest Laboratories
Unipolar Depression
Open Study Assessing the Feasibility of Minocycline in Patients With Unipolar Depression
A single center, open label study assessing the feasibility, safety and therapeutic effect of Minocycline in adult patients with diagnosis of unipolar depression.
- Trial name
- NCT01574742
- Testing
- Minocycline
- Where
- Israel
- Volunteers
- 30 people
- Sponsor
- Shalvata Mental Health Center
Major Depressive Disorder, Depression, Unipolar
Low-Dose Naltrexone (LDN) for Depression Relapse and Recurrence
The purpose of this pilot study is to determine if taking a low dose of naltrexone in addition to an antidepressant medication can help treat relapse or recurrence in people with Major Depressive Disorder (MDD). The U.S.
- Conditions
- Major Depressive Disorder, Depression, Unipolar, Recurrence, Relapse
- Trial name
- NCT01874951
- Testing
- Naltrexone
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Massachusetts General Hospital
Major Depressive Disorder
Major Depressive Disorder Study In Adults
A study to obtain safety and tolerability data
- Trial name
- NCT00049972
- Testing
- paroxetine CR
- Where
- 71 sites in United States
- Volunteers
- 646 people
- Sponsor
- GlaxoSmithKline
Major Depressive Disorder
MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy
This randomized, double-blind, placebo-controlled, parallel group study will evaluate the safety and efficacy of RO4917523 as adjunctive therapy in patients with major depressive disorder and an inadequate response to ongoing…
- Trial name
- NCT01437657
- Testing
- RO4917523 0.5 mg, RO4917523 1.5 mg
- Where
- 76 sites in United States, Chile and 7 more
- Volunteers
- 319 people
- Sponsor
- Hoffmann-La Roche
Bipolar Depression
Study to Evaluate the Effects of Switching Different Strength Forms of FK949E in Bipolar Disorder Patients With Major Depressive Episodes
The purpose of this study was to evaluate the efficacy, safety, and pharmacokinetics of switching FK949E (sustained-release quetiapine) 50-mg and 150-mg tablets to the other tablet at the equivalent total daily dose in bipolar…
- Trial name
- NCT02362412
- Testing
- FK949E
- Where
- 7 sites in Japan
- Volunteers
- 22 people
- Sponsor
- Astellas Pharma Inc
Depression, Cognition
Study of Duloxetine in Elderly Patients With Major Depressive Disorder
A study of the safety and efficacy of duloxetine in elderly patients (greater than 65 years old) with major depressive disorder
- Trial name
- NCT00062673
- Testing
- Duloxetine
- Where
- United States
- Volunteers
- 311 people
- Sponsor
- Eli Lilly and Company
Depressive Disorder, Major
A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy
The purpose of this study is to assess the efficacy of seltorexant compared with quetiapine extended-release (XR) as adjunctive therapy to an antidepressant drug in treatment response in participants with major depressive…
- Trial name
- NCT04513912
- Testing
- Seltorexant, Quetiapine XR
- Where
- 175 sites in United States, Argentina and 13 more
- Volunteers
- 757 people
- Sponsor
- Janssen Research & Development, LLC
Depression, Depressive Disorder
Stimulation of Parieto-hippocampal Connectivity in Patients With Major Depressive Disorder
This study aims to investigate the effects of individualized repetitive transcranial magnetic stimulation (rTMS) of parieto-hippocampal functional connectivity in patients with major depressive disorder (MDD).
- Conditions
- Depression, Depressive Disorder, Depressive Episode, Depressive Disorder, Major
- Trial name
- NCT04081519
- Testing
- active rTMS over DLPFC, Add-on active rTMS over DLPFC, Add-on active rTMS over LPC
- Where
- Germany
- Volunteers
- 53 people
- Sponsor
- University Hospital, Bonn
Major Depressive Disorder
Efficacy, Safety and Tolerability of Agomelatine Sublingual Tablets in the Treatment of Major Depressive Disorder (MDD)
The study will assess efficacy, safety and tolerability of 0.5 mg/day and 1 mg/day of sublingual (under the tongue) formulation of agomelatine in patients with Major Depressive Disorder.
- Trial name
- NCT01110902
- Testing
- Agomelatine (AGO178C)
- Where
- 45 sites in United States, Puerto Rico
- Volunteers
- 589 people
- Sponsor
- Novartis Pharmaceuticals
Anxiety State
Music Listening to Lower Anxiety During ECT Treatment.
The purpose of this study is to assess whether music listening is helpful in lowering anxiety in patients about to start their ECT treatment.
- Trial name
- MIECT (NCT04706728)
- Testing
- Listening to playlists with music prior to-, during and after the ECT procedure, Listening to playlists with sound from nature (rain, waves) prior to-, during and after the ECT procedure
- Where
- Denmark
- Volunteers
- 24 people
- Sponsor
- Aalborg University